Industries

SHERIDAN, WYOMING – July 25, 2025 – Roche has officially discontinued development of CT-173, an investigational PYY analog once positioned as a novel obesity treatment, citing a lack of competitiveness and development potential in its latest strategic assessment.

The decision, announced during the company’s second-quarter earnings call, marks a clear pivot in Roche’s prioritization within its obesity drug pipeline, following its high-profile acquisition of Carmot Therapeutics for $2.7 billion in December 2023. The move reflects Roche’s sharpened focus on only the most promising assets as the obesity drug market becomes increasingly competitive.

Early-stage candidate fails to meet internal thresholds

SHERIDAN, WYOMING – July 25, 2025 – Roche has reported strong momentum in the first half of 2025, achieving 7% sales growth at constant exchange rates (CER) and a 23% increase in IFRS net income, driven by high demand for innovative pharmaceutical treatments and effective cost control measures.

Strong Performance in Pharmaceuticals Drives Growth

Roche’s Pharmaceuticals Division delivered a standout performance, with sales rising 10% (CER) to CHF 24.0 billion. This increase was propelled by robust demand for key therapies including Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus, which together contributed CHF 10.6 billion in sales — a CHF 1.7 billion increase over the same period last year.

SHERIDAN, WYOMING – July 25, 2025 – Roche has received CE Mark certification for its Elecsys® pTau181 blood test, marking a pivotal advancement in Alzheimer’s diagnostics by introducing the first IVDR-certified in-vitro diagnostic test to help rule out Alzheimer’s-associated amyloid pathology. Developed in collaboration with Eli Lilly and Company, the test is designed to help clinicians exclude Alzheimer’s disease as the cause of cognitive decline using a simple blood sample, significantly reducing the need for invasive confirmatory procedures like PET scans or CSF analysis.

Minimally Invasive Test Aims to Address Diagnostic Gaps

SHERIDAN, WYOMING – July 25, 2025 – Roche has received European Commission (EC) approval for Itovebi™ (inavolisib), a targeted therapy for adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer. The approval marks a significant milestone in the treatment of a subtype associated with poor prognosis and limited therapeutic options.

Regulatory milestone based on robust clinical evidence

The EC’s decision was driven by data from the pivotal phase III INAVO120 study, published in The New England Journal of Medicine in October 2024. The trial demonstrated that the Itovebi-based regimen—when used in combination with palbociclib (Ibrance®) and fulvestrant—more than doubled progression-free survival (15.0 months vs. 7.3 months; HR=0.43; p<0.001) compared with palbociclib and fulvestrant alone.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced a significant step in the modernization of its capital structure, as its Board of Directors proposes to exchange the company's non-voting equity securities ("Genussscheine") for newly issued participation certificates. The proposal, which will be submitted to shareholders for approval at the 2026 Annual General Meeting (AGM), aims to align Roche’s capital instruments with current Swiss corporate law and modern market practices.

The proposed participation certificates will carry a nominal value of CHF 0.001 each and be listed on the SIX Swiss Exchange, offering the same economic value and entitlements as the Genussscheine they replace. In tandem, Roche also plans to reduce the nominal value of its bearer shares from CHF 1.00 to CHF 0.001 per share. This will result in a cash repayment of CHF 0.999 per bearer share, totaling approximately CHF 106.6 million, contingent on shareholder approval.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced topline results from two pivotal clinical trials evaluating astegolimab for chronic obstructive pulmonary disease (COPD), highlighting a complex development path for the investigational monoclonal antibody. The phase IIb ALIENTO trial met its primary endpoint, while the phase III ARNASA trial did not, despite both showing numerical reductions in exacerbation rates.

Phase IIb ALIENTO Achieves Statistically Significant Reduction in Exacerbations

The ALIENTO study, which enrolled 1,301 patients, demonstrated a statistically significant 15.4% reduction in the annualised exacerbation rate (AER) over 52 weeks when astegolimab was administered every two weeks on top of standard COPD maintenance therapy. The patient population included both current and former smokers, regardless of blood eosinophil count, with a history of frequent exacerbations.

SHERIDAN, WYOMING – July 25, 2025 – Küppersbusch Hausgeräte GmbH will present a fully redesigned dishwasher product line during Küchenmeile 2025, marking a significant milestone in the company’s strategic product development roadmap. Hosted in the brand’s showroom at Gut Böckel, this major industry event underscores Küppersbusch’s ongoing commitment to design excellence, energy efficiency, and market-driven innovation.

Showcasing Innovation and Strategic Expansion

Under the guiding theme “Inspire 2025: Impulse. Innovation. Interaktion.”, Küppersbusch invites trade partners, planners, and kitchen specialists to engage directly with its brand environment and explore key innovations that will shape the upcoming kitchen season. The introduction of an entirely new dishwasher portfolio marks a pivotal moment in the company's expansion efforts.

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has reaffirmed its long-term strategic transformation during its virtual Annual General Meeting (AGM) for fiscal year 2024/2025, underscoring the company’s commitment to becoming a systems integrator in packaging and to expanding into new technology-driven markets.

With approximately 27.5 percent of HEIDELBERG's share capital represented, the Management Board presented a comprehensive overview of the company’s financial performance, strategic progress, and outlook through a live-streamed session for shareholders and stakeholder representatives.

Positioning HEIDELBERG for the Future

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has signed an agreement with the Polar Group to acquire the technology, brand rights, and intellectual property (IP) of the renowned postpress specialist Polar Mohr, marking a pivotal step in its expansion strategy for the packaging and label market. The acquisition will give HEIDELBERG exclusive global rights for sales, service, and marketing of Polar Mohr postpress products, further solidifying its position as a comprehensive systems integrator.

Strategic Growth through Consolidation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced a significant leadership transition, positioning its executive team for continued strategic growth in the musculoskeletal technology sector. Effective July 18, 2025, Keith Pfeil assumed the role of President and Chief Executive Officer, succeeding Daniel Scavilla, who stepped down to pursue another opportunity. Additionally, Kyle Kline was appointed Senior Vice President and Chief Financial Officer.

Leadership Shifts Focused on Strategic Growth

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has scheduled the announcement of its financial results for the second quarter ended June 30, 2025, for Thursday, August 7, 2025, after market close. The musculoskeletal technology leader will publish the earnings release on its investor relations website at www.investors.globusmedical.com.

Investor Call Scheduled for August 7

Following the earnings release, Globus Medical will host a teleconference with the investment community at 4:30 p.m. Eastern Time on the same day. The company offers multiple ways for stakeholders to join the event:

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. has announced the expansion of its Excelsius™ navigation capabilities with the introduction of DuraPro™, a next-generation oscillating system designed to enhance surgical precision while safeguarding delicate tissue. As part of the company’s Power Portfolio, DuraPro™ aims to optimize procedural workflows by combining advanced oscillating technology with integrated navigation.

Advancing the High-Speed Drill Market with Next-Generation Oscillation

SHERIDAN, WYOMING – July 22, 2025 – Globus Medical, Inc. (NYSE: GMED), a global leader in musculoskeletal solutions, today announced a significant strategic initiative with the authorization of a share repurchase program of up to $500 million of the company’s outstanding common stock. The move underscores Globus Medical’s confidence in its long-term business fundamentals and commitment to delivering sustained value for shareholders.

Strategic Response to Market Valuation Trends

SHERIDAN, WYOMING – July 21, 2025 – Sidel’s Beijing Plant has successfully completed the full grid connection of its rooftop solar photovoltaic (PV) system, a major milestone in the company’s global decarbonisation strategy. With thousands of panels now installed, the initiative underscores Sidel’s ongoing commitment to sustainable manufacturing and sets a new benchmark for green transformation in the industrial sector.

Driving Low-Carbon Operations with High-Efficiency Solar Power

The solar installation, boasting an installed capacity of 2.1 megawatts, is projected to generate approximately 4.39 million kilowatt-hours of electricity annually. This output is expected to cover 60% of the plant’s operational energy needs, contributing to a reduction of 2,452 tonnes of CO₂ emissions per year.

SHERIDAN, WYOMING – July 21, 2025 – Gentlebrand, a Sidel company, will present its latest beverage packaging innovations at drinktec 2025, the world’s leading exhibition for beverage industry innovation, taking place from September 15–19 at Messe München, Germany. At Hall C5, Booth 627, Gentlebrand will highlight its ability to merge tradition with innovation through striking packaging concepts designed for real-world production.

Bringing Iconic Packaging Concepts to Life

Gentlebrand’s showcase will feature a preview of its newest collaborations with Argea, Toshmineralsuv, ROSAE, and Zelda Smartweight Water. The designs reflect the company’s philosophy of delivering market-ready solutions that balance visual appeal with production efficiency.

Key highlights include:

SHERIDAN, WYOMING – July 21, 2025 – Gentlebrand, a Sidel company, has recently partnered with Angola-based REFITEC to develop Boavista, a vegetable and soya oil brand designed to embody Angola’s cultural heritage through a refreshed, contemporary visual identity. This strategic collaboration brought together creative expertise and local authenticity to craft a product that resonates with tradition while appealing to modern consumers.

A Strategic Partnership Rooted in Tradition

REFITEC, known for its commitment to promoting authentic local products, entrusted Gentlebrand with the challenge of creating a brand identity that honors Angola’s rich heritage. The goal was clear: to reinforce Boavista’s local roots while making it relevant and attractive to new generations.

SHERIDAN, WYOMING – July 21, 2025 – Sidel, a global leader in packaging solutions and industrial innovation, has announced the launch of its inaugural summer camp at the company’s Octeville-sur-Mer site in France. This initiative aims to attract and nurture aspiring engineers by offering an immersive, hands-on experience that blends skill development with real-world industry exposure.

Empowering Students Through Practical Experience

The Sidel summer camp will run from July 7 to 11, 2025, and will host 20 engineering students aged between 21 and 25 from selected partner universities. Designed as a free, five-day program, the camp will provide participants with an opportunity to engage in hands-on workshops, collaborative problem-solving exercises, and a live challenge focused on designing a customer-oriented product prototype.

SHERIDAN, WYOMING – July 21, 2025 – Gentlebrand Design Agency, part of the Sidel family, has partnered with Uzbekistan-based Toshmineralsuv to deliver a strategic redesign of its iconic Tashkentskaya mineral water, introducing a sleek PET bottle that strengthens the brand’s premium positioning while honoring its legacy.

Renowned for its purity and sourced from a natural spring 1,371 meters underground, Tashkentskaya mineral water now debuts in a refined PET format aimed at enhancing market presence and consumer appeal. This initiative underscores Gentlebrand’s ability to blend deep brand insight with bold creative execution in competitive consumer markets.

SHERIDAN, WYOMING – July 21, 2025 – Sidel has introduced CoboREEL™, a cobot-powered automated reel loading solution that sets a new benchmark in beverage packaging by offering the industry’s highest reel autonomy with a capacity of up to 18 reels. Developed to meet the rising global demand for PET-packaged beverages, CoboREEL addresses key industry challenges of efficiency, workforce optimization, and profitability.

Boosting Labelling Efficiency for a Growing Beverage Market

With global packaged water volumes forecasted to have risen by 3.5% and carbonated beverages by 2.2% by 2029, beverage producers are under increasing pressure to optimize production efficiency and cost management. Sidel’s CoboREEL directly responds to this demand by automating the repetitive reel loading process, enhancing accuracy and minimizing production downtime.

By leveraging integrated cobot technology, CoboREEL:

SHERIDAN, WYOMING – July 21, 2025 – Sidel has announced the successful renewal of its Qualiopi certification for 2025, reaffirming its position as a leading provider of high-quality, customer-centric vocational training for the packaging industry worldwide. This milestone underscores Sidel’s long-term commitment to enhancing operational efficiency and maintaining the highest standards of safety, product quality, and line performance for its clients.

Renewed Certification Confirms Global Training Excellence

The Qualiopi certification — granted by accredited entities recognized by the French Government — confirms the quality, consistency, and impact of Sidel’s vocational training programs. Following a rigorous audit, the Sidel Training Centre was found to be fully compliant with all 32 indicators of the French national quality reference framework.